(FME) Fresenius Medical Care - Overview
Exchange: XETRA •
Country: Germany •
Currency: EUR •
Type: Common Stock •
ISIN: DE0005785802
Stock: Dialysis Machines, Dialysis Solutions, Bloodlines, Water Systems, Pharma
Total Rating 35
Risk 81
Buy Signal -0.59
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 2.82% |
| Yield on Cost 5y | 2.89% |
| Yield CAGR 5y | 1.82% |
| Payout Consistency | 97.7% |
| Payout Ratio | 50.5% |
| Risk 5d forecast | |
|---|---|
| Volatility | 36.6% |
| Relative Tail Risk | -15.6% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.38 |
| Alpha | -15.64 |
| Character TTM | |
|---|---|
| Beta | 0.069 |
| Beta Downside | 0.039 |
| Drawdowns 3y | |
|---|---|
| Max DD | 36.77% |
| CAGR/Max DD | 0.15 |
Description: FME Fresenius Medical Care January 02, 2026
Fresenius Medical Care AG & Co. KGaA (XETRA:FME) is the world’s largest provider of dialysis and related renal-care services, operating a network of outpatient clinics and hospital contracts in Germany, the United States, and other markets.
The business is split into two segments: **Care Delivery**, which runs the clinics and hospital-based dialysis services, and **Care Enablement**, which manufactures and distributes dialysis equipment (hemodialysis machines, peritoneal dialysis cyclers), consumables (dialyzers, concentrates, water-treatment systems), and renal pharmaceuticals.
Key recent metrics (FY 2023) show revenue of €19.4 bn, an EBITDA margin of ~23 %, and a 13 % year-over-year increase in US dialysis-clinic patient volume, reflecting both demographic aging and higher ESRD prevalence. The company’s growth is also tied to reimbursement trends in the U.S. Medicare-ESRD program and to its expanding home-dialysis offering, which benefits from policy incentives for cost-effective, patient-centric care.
For a deeper, data-driven assessment of FME’s valuation and risk profile, you may find the analyst tools on ValueRay useful for independent verification.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 718.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 0.94 > 1.0 |
| NWC/Revenue: 10.51% < 20% (prev 11.45%; Δ -0.93% < -1%) |
| CFO/TA 0.08 > 3% & CFO 2.51b > Net Income 718.2m |
| Net Debt (9.22b) to EBITDA (3.14b): 2.93 < 3 |
| Current Ratio: 1.36 > 1.5 & < 3 |
| Outstanding Shares: last quarter (292.1m) vs 12m ago -0.45% < -2% |
| Gross Margin: 25.00% > 18% (prev 0.25%; Δ 2475 % > 0.5%) |
| Asset Turnover: 61.97% > 50% (prev 59.18%; Δ 2.79% > 0%) |
| Interest Coverage Ratio: 3.98 > 6 (EBITDA TTM 3.14b / Interest Expense TTM 386.4m) |
Altman Z'' 2.66
| A: 0.07 (Total Current Assets 7.82b - Total Current Liabilities 5.76b) / Total Assets 30.89b |
| B: 0.38 (Retained Earnings 11.84b / Total Assets 30.89b) |
| C: 0.05 (EBIT TTM 1.54b / Avg Total Assets 31.70b) |
| D: 0.62 (Book Value of Equity 10.47b / Total Liabilities 16.98b) |
| Altman-Z'' Score: 2.66 = A |
Beneish M -3.08
| DSRI: 0.98 (Receivables 3.28b/3.28b, Revenue 19.64b/19.24b) |
| GMI: 1.01 (GM 25.00% / 25.14%) |
| AQI: 1.01 (AQ_t 0.54 / AQ_t-1 0.54) |
| SGI: 1.02 (Revenue 19.64b / 19.24b) |
| TATA: -0.06 (NI 718.2m - CFO 2.51b) / TA 30.89b) |
| Beneish M-Score: -3.08 (Cap -4..+1) = AA |
What is the price of FME shares?
As of February 08, 2026, the stock is trading at EUR 40.64 with a total of 1,029,840 shares traded.
Over the past week, the price has changed by +7.20%, over one month by +1.04%, over three months by -3.33% and over the past year by -11.13%.
Over the past week, the price has changed by +7.20%, over one month by +1.04%, over three months by -3.33% and over the past year by -11.13%.
Is FME a buy, sell or hold?
Fresenius Medical Care has no consensus analysts rating.
What are the forecasts/targets for the FME price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 45.1 | 11% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 41 | 0.9% |
FME Fundamental Data Overview February 03, 2026
Market Cap USD = 13.19b (11.18b EUR * 1.1801 EUR.USD)
P/E Trailing = 15.6148
P/E Forward = 9.009
P/S = 0.5691
P/B = 0.8486
P/EG = 0.3562
Revenue TTM = 19.64b EUR
EBIT TTM = 1.54b EUR
EBITDA TTM = 3.14b EUR
Long Term Debt = 6.32b EUR (from longTermDebt, last quarter)
Short Term Debt = 1.14b EUR (from shortTermDebt, last quarter)
Debt = 10.47b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 9.22b EUR (from netDebt column, last quarter)
Enterprise Value = 20.40b EUR (11.18b + Debt 10.47b - CCE 1.26b)
Interest Coverage Ratio = 3.98 (Ebit TTM 1.54b / Interest Expense TTM 386.4m)
EV/FCF = 11.47x (Enterprise Value 20.40b / FCF TTM 1.78b)
FCF Yield = 8.72% (FCF TTM 1.78b / Enterprise Value 20.40b)
FCF Margin = 9.05% (FCF TTM 1.78b / Revenue TTM 19.64b)
Net Margin = 3.66% (Net Income TTM 718.2m / Revenue TTM 19.64b)
Gross Margin = 25.00% ((Revenue TTM 19.64b - Cost of Revenue TTM 14.73b) / Revenue TTM)
Gross Margin QoQ = 25.43% (prev 25.34%)
Tobins Q-Ratio = 0.66 (Enterprise Value 20.40b / Total Assets 30.89b)
Interest Expense / Debt = 0.89% (Interest Expense 93.1m / Debt 10.47b)
Taxrate = 18.69% (75.2m / 402.6m)
NOPAT = 1.25b (EBIT 1.54b * (1 - 18.69%))
Current Ratio = 1.36 (Total Current Assets 7.82b / Total Current Liabilities 5.76b)
Debt / Equity = 0.81 (Debt 10.47b / totalStockholderEquity, last quarter 12.95b)
Debt / EBITDA = 2.93 (Net Debt 9.22b / EBITDA 3.14b)
Debt / FCF = 5.18 (Net Debt 9.22b / FCF TTM 1.78b)
Total Stockholder Equity = 13.79b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.27% (Net Income 718.2m / Total Assets 30.89b)
RoE = 5.21% (Net Income TTM 718.2m / Total Stockholder Equity 13.79b)
RoCE = 7.64% (EBIT 1.54b / Capital Employed (Equity 13.79b + L.T.Debt 6.32b))
RoIC = 6.02% (NOPAT 1.25b / Invested Capital 20.76b)
WACC = 3.54% (E(11.18b)/V(21.65b) * Re(6.17%) + D(10.47b)/V(21.65b) * Rd(0.89%) * (1-Tc(0.19)))
Discount Rate = 6.17% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -81.65 | Cagr: -0.22%
[DCF Debug] Terminal Value 86.73% ; FCFF base≈1.69b ; Y1≈1.76b ; Y5≈2.02b
Fair Price DCF = 175.6 (EV 60.10b - Net Debt 9.22b = Equity 50.89b / Shares 289.8m; r=5.90% [WACC]; 5y FCF grow 4.39% → 2.90% )
EPS Correlation: 60.54 | EPS CAGR: 9.60% | SUE: 0.05 | # QB: 0
Revenue Correlation: 29.93 | Revenue CAGR: 1.34% | SUE: 0.55 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.95 | Chg30d=-0.027 | Revisions Net=+1 | Analysts=2
EPS next Year (2026-12-31): EPS=4.04 | Chg30d=-0.130 | Revisions Net=-8 | Growth EPS=+4.0% | Growth Revenue=+2.2%
P/E Trailing = 15.6148
P/E Forward = 9.009
P/S = 0.5691
P/B = 0.8486
P/EG = 0.3562
Revenue TTM = 19.64b EUR
EBIT TTM = 1.54b EUR
EBITDA TTM = 3.14b EUR
Long Term Debt = 6.32b EUR (from longTermDebt, last quarter)
Short Term Debt = 1.14b EUR (from shortTermDebt, last quarter)
Debt = 10.47b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 9.22b EUR (from netDebt column, last quarter)
Enterprise Value = 20.40b EUR (11.18b + Debt 10.47b - CCE 1.26b)
Interest Coverage Ratio = 3.98 (Ebit TTM 1.54b / Interest Expense TTM 386.4m)
EV/FCF = 11.47x (Enterprise Value 20.40b / FCF TTM 1.78b)
FCF Yield = 8.72% (FCF TTM 1.78b / Enterprise Value 20.40b)
FCF Margin = 9.05% (FCF TTM 1.78b / Revenue TTM 19.64b)
Net Margin = 3.66% (Net Income TTM 718.2m / Revenue TTM 19.64b)
Gross Margin = 25.00% ((Revenue TTM 19.64b - Cost of Revenue TTM 14.73b) / Revenue TTM)
Gross Margin QoQ = 25.43% (prev 25.34%)
Tobins Q-Ratio = 0.66 (Enterprise Value 20.40b / Total Assets 30.89b)
Interest Expense / Debt = 0.89% (Interest Expense 93.1m / Debt 10.47b)
Taxrate = 18.69% (75.2m / 402.6m)
NOPAT = 1.25b (EBIT 1.54b * (1 - 18.69%))
Current Ratio = 1.36 (Total Current Assets 7.82b / Total Current Liabilities 5.76b)
Debt / Equity = 0.81 (Debt 10.47b / totalStockholderEquity, last quarter 12.95b)
Debt / EBITDA = 2.93 (Net Debt 9.22b / EBITDA 3.14b)
Debt / FCF = 5.18 (Net Debt 9.22b / FCF TTM 1.78b)
Total Stockholder Equity = 13.79b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.27% (Net Income 718.2m / Total Assets 30.89b)
RoE = 5.21% (Net Income TTM 718.2m / Total Stockholder Equity 13.79b)
RoCE = 7.64% (EBIT 1.54b / Capital Employed (Equity 13.79b + L.T.Debt 6.32b))
RoIC = 6.02% (NOPAT 1.25b / Invested Capital 20.76b)
WACC = 3.54% (E(11.18b)/V(21.65b) * Re(6.17%) + D(10.47b)/V(21.65b) * Rd(0.89%) * (1-Tc(0.19)))
Discount Rate = 6.17% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -81.65 | Cagr: -0.22%
[DCF Debug] Terminal Value 86.73% ; FCFF base≈1.69b ; Y1≈1.76b ; Y5≈2.02b
Fair Price DCF = 175.6 (EV 60.10b - Net Debt 9.22b = Equity 50.89b / Shares 289.8m; r=5.90% [WACC]; 5y FCF grow 4.39% → 2.90% )
EPS Correlation: 60.54 | EPS CAGR: 9.60% | SUE: 0.05 | # QB: 0
Revenue Correlation: 29.93 | Revenue CAGR: 1.34% | SUE: 0.55 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.95 | Chg30d=-0.027 | Revisions Net=+1 | Analysts=2
EPS next Year (2026-12-31): EPS=4.04 | Chg30d=-0.130 | Revisions Net=-8 | Growth EPS=+4.0% | Growth Revenue=+2.2%